DK1368025T3 - Præparater, der er nyttige til behandling af patologier, som udviser respons på aktiveringen af PPAR-gammareceptor - Google Patents

Præparater, der er nyttige til behandling af patologier, som udviser respons på aktiveringen af PPAR-gammareceptor

Info

Publication number
DK1368025T3
DK1368025T3 DK02717031T DK02717031T DK1368025T3 DK 1368025 T3 DK1368025 T3 DK 1368025T3 DK 02717031 T DK02717031 T DK 02717031T DK 02717031 T DK02717031 T DK 02717031T DK 1368025 T3 DK1368025 T3 DK 1368025T3
Authority
DK
Denmark
Prior art keywords
activation
treatment
pathologies
compositions useful
gamma receptor
Prior art date
Application number
DK02717031T
Other languages
Danish (da)
English (en)
Inventor
C Sigma-Tau Industr Far Pisano
T Sigma-Tau Indus Far Riccioni
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of DK1368025T3 publication Critical patent/DK1368025T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK02717031T 2001-03-16 2002-03-01 Præparater, der er nyttige til behandling af patologier, som udviser respons på aktiveringen af PPAR-gammareceptor DK1368025T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000136A ITRM20010136A1 (it) 2001-03-16 2001-03-16 Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.
PCT/IT2002/000127 WO2002074291A2 (en) 2001-03-16 2002-03-01 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor

Publications (1)

Publication Number Publication Date
DK1368025T3 true DK1368025T3 (da) 2005-12-19

Family

ID=11455333

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02717031T DK1368025T3 (da) 2001-03-16 2002-03-01 Præparater, der er nyttige til behandling af patologier, som udviser respons på aktiveringen af PPAR-gammareceptor

Country Status (19)

Country Link
US (4) US6897235B2 (cs)
EP (1) EP1368025B1 (cs)
JP (1) JP4276842B2 (cs)
KR (1) KR100851678B1 (cs)
CN (2) CN1286456C (cs)
AT (1) ATE308984T1 (cs)
AU (1) AU2002247951B2 (cs)
BR (1) BR0208157A (cs)
CA (1) CA2440979C (cs)
CZ (1) CZ20032523A3 (cs)
DE (1) DE60207215T2 (cs)
DK (1) DK1368025T3 (cs)
ES (1) ES2249568T3 (cs)
HU (1) HUP0303518A3 (cs)
IT (1) ITRM20010136A1 (cs)
MX (1) MXPA03008317A (cs)
PL (1) PL369295A1 (cs)
SK (1) SK12752003A3 (cs)
WO (1) WO2002074291A2 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
ES2327639T3 (es) * 2003-05-14 2009-11-02 Dsm Ip Assets B.V. Uso de derivados de ftalida para el tratamiento y prevecion de diabetes mellitus.
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
KR20090066289A (ko) 2006-09-08 2009-06-23 로드아일랜드하스피틀 알코올 유발성 뇌 질환의 치료, 예방 및 역행

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07285862A (ja) * 1994-04-21 1995-10-31 Kokka Iyaku Kanrikyoku Shisen Kokinso Kogyo Kenkyusho 脂質低下剤
JPH107557A (ja) * 1996-06-17 1998-01-13 Banyu Pharmaceut Co Ltd 抗腫瘍性物質スピロラキシン
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
IT1317001B1 (it) * 2000-03-13 2003-05-26 Sigma Tau Ind Farmaceuti Uso della spirolaxina per il trattamento di patologie associate ad unaalterata angiogenesi.

Also Published As

Publication number Publication date
ATE308984T1 (de) 2005-11-15
US20050131060A1 (en) 2005-06-16
US20040241228A1 (en) 2004-12-02
US6897235B2 (en) 2005-05-24
HK1096850A1 (zh) 2007-06-15
HUP0303518A3 (en) 2005-12-28
JP4276842B2 (ja) 2009-06-10
US20040092540A1 (en) 2004-05-13
CA2440979C (en) 2010-07-13
US20040242675A1 (en) 2004-12-02
CN1286456C (zh) 2006-11-29
CZ20032523A3 (cs) 2004-05-12
ITRM20010136A1 (it) 2002-09-16
CN1839823A (zh) 2006-10-04
HK1075006A1 (en) 2005-12-02
JP2004523578A (ja) 2004-08-05
SK12752003A3 (sk) 2004-01-08
MXPA03008317A (es) 2003-12-11
WO2002074291A2 (en) 2002-09-26
HUP0303518A2 (hu) 2004-03-01
DE60207215D1 (de) 2005-12-15
EP1368025A2 (en) 2003-12-10
CN1610545A (zh) 2005-04-27
ITRM20010136A0 (it) 2001-03-16
AU2002247951B2 (en) 2007-03-01
CA2440979A1 (en) 2002-09-26
KR20040025905A (ko) 2004-03-26
ES2249568T3 (es) 2006-04-01
EP1368025B1 (en) 2005-11-09
BR0208157A (pt) 2004-03-02
PL369295A1 (en) 2005-04-18
WO2002074291A3 (en) 2003-03-13
DE60207215T2 (de) 2006-07-20
KR100851678B1 (ko) 2008-08-13
CN100462073C (zh) 2009-02-18
US7276533B2 (en) 2007-10-02

Similar Documents

Publication Publication Date Title
DK1379239T3 (da) N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
DK1177176T3 (da) Triarylsyrederivater som PPAR-receptorligander
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
CL2004000655A1 (es) Compuestos derivados de piperidin-2-ona 1,6-disustituidos, sus sales, composicion farmaceutica, agonistas del receptor ep4; uso de los compuestos para tratar hipertension ocular, glaucoma.
BR0112030A (pt) Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
CY1109989T1 (el) 3,4-di-υποκαθισταμενες cyclobutene-1,2-diones ως συνδετες του υποδοχεα των cxc-χημειοκινων
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
SE0201544D0 (sv) Novel compounds and thier use
DK1467706T3 (da) Dermalt applikationssystem for aminolevulinsyre-derivater
NO20074544L (no) Inhibering av HER2-losriving med matriksmetalloproteaseantagonister
ATE368023T1 (de) Hydroxydiphenyletherverbindungen
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
ECSP055986A (es) Derivados de ácido 3-(2-fenil-oxazol-4-ilmetoxi)ciclohexilmetoxiacético y compuestos relacionados utilizados como moduladores de ppar para tratar diabetes de tipo 2 y arterioesclerosis
NO20054787D0 (no) Indenderivater som farmasotiske midler
DK1408966T3 (da) Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes
DK0752854T3 (da) Pyrimidin- eller triazincarboxylsyrederivater til anvendelse som lægemiddel
SE9804212D0 (sv) Compounds
MA29485B1 (fr) Motilides
ATE433458T1 (de) Modulatoren von ship-1
DK1388542T3 (da) Anvendelse af hederagenin 3-0-a-L-rhamnopyranosyl((1->2)-[beta-D-glucopyranosyl(1->4)]-a-L-arabinopyranosid eller en ekstrakt fra Pulsatillae radix indeholdende samme som et terapeutisk middel til faste tumorer
PL369295A1 (en) Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis